EBS earnings: real EPS beat/miss history, analyst consensus Buy, P/E -44.59. Updated 2026-07-23.
Emergent BioSolutions (EBS) Research Hub
Emergent BioSolutions (EBS) trades on NYSE, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 6.23 USD (+9.68%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -44.59, market cap 0.39B. This hub links to the full technical, earnings and options research available for EBS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NYSE, US |
| Last close | 6.23 USD (+9.68%) |
| 52-week range | 4.37 USD – 8.54 USD |
| Trend regime | Range |
| 14-day RSI | 70.5 (Overbought) |
| Trailing P/E | -44.59 |
| Market cap | 0.39B |
| Dividend yield | 0.00% |
Available research for EBS
Covered Call on EBS: how it works, illustrative setup around the real 6.23 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on EBS: how it works, illustrative setup around the real 6.23 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on EBS: how it works, illustrative setup around the real 6.23 USD price, max profit/loss, breakeven and when to use it. Educational.
EBS technical analysis: range, last 6.23 USD, RSI 70.5, 52w range 4.37 USD–8.54 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is EBS in?
Emergent BioSolutions (EBS) is classified under Healthcare (Biotechnology), listed on NYSE, US.
Is EBS in an uptrend or downtrend?
As of 2026-09-11, EBS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is EBS's trailing P/E ratio?
EBS's trailing P/E is -44.59, with a market cap of 0.39B. See the earnings research page for full valuation detail.